https://doi.org/10.55788/1e2c0917
“LAAC is indicated in patients with an increased risk of stroke and an appropriate rationale to avoid long-term OAC,” explained Prof. Oussama Wazni (Cleveland Clinic, OH, USA) [1]. “However, it has not been studied in patients undergoing ablation for AF.”
The OPTION trial (NCT03795298) assessed LAAC and OAC in patients with AF who underwent ablation and were at a moderate-to-high risk of stroke [2]. Participants with AF indicated for ablation (n=1,600) were randomised 1:1 to ablation plus LAAC (WATCHMAN FLX) or ablation plus OAC. “Participants in the LAAC arm received OAC plus aspirin for 3 months, after which they continued on aspirin only,” added Prof. Wazni [1]. The primary endpoint was a composite of all-cause death, stroke, or systemic embolism at 36 months, which was tested for non-inferiority. The primary safety endpoint was non-procedural ISTH major bleeding or clinically relevant non-major bleeding at 36 months, which was tested for superiority. “About 95% of the participants on OACs received direct OACs [DOACs],” said Prof. Wazni.
At 36 months, ablation plus LAAC was non-inferior to ablation plus OAC for efficacy, with incidence rates of 5.3% and 5.8%, respectively (HR 0.91; 95% CI 0.59–1.39; Pnon-inferiority<0.0001). Regarding the primary safety endpoint, ablation plus LAAC was superior to ablation plus OAC, with rates of 8.5% and 18.1% (HR 0.44; 95% CI 0.33–0.59; P<0.0001; see Figure).
Figure: Primary safety endpoint met superiority in the OPTION study [1]

OAC, oral anticoagulation.
“WATCHMAN FLX is a safe and effective first-line option for patients with AF undergoing ablation,” concluded Prof. Wazni. “Interestingly, 40% of the patients in the study received a concomitant ablation and LAAC procedure, potentially reducing AF burden, the risk for stroke, and the risk for bleeding in one procedure.”
- Wazni OM, et al. Randomised comparison of left atrial appendage closure with oral anticoagulation after catheter ablation for atrial fibrillation. LBS.02, AHA Scientific Sessions 2024, 16–18 November, Chicago, USA.
- Wazni OM, et al. N Engl J Med 2024; Nov 16. DOI: 10.1056/NEJMoa2408308.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« Head-to-head: Cryoballoon vs radiofrequency ablation in persistent AF Next Article
VANISH2: Antiarrhythmic drug therapy or catheter ablation in prior myocardial infarction complicated by ventricular tachycardia? »
« Head-to-head: Cryoballoon vs radiofrequency ablation in persistent AF Next Article
VANISH2: Antiarrhythmic drug therapy or catheter ablation in prior myocardial infarction complicated by ventricular tachycardia? »
Table of Contents: AHA 2024
Featured articles
Ablation for Arrhythmias
PROMPT-AF: Novel ablation strategy improves outcomes for persistent AF
ARREST-AF: The true impact of risk factor management on AF recurrence after ablation
VANISH2: Antiarrhythmic drug therapy or catheter ablation in prior myocardial infarction complicated by ventricular tachycardia?
OPTION: LAAC over OAC after ablation in patients with AF and increased stroke risk
Head-to-head: Cryoballoon vs radiofrequency ablation in persistent AF
Novel Treatment Options in Heart Failure
Will myeloperoxidase inhibition benefit patients with heart failure?
Is intranasal bumetanide a viable diuretic option in congestive HF?
REALIZE-K: MRA treatment optimisation in HFrEF plus hyperkalaemia
SUMMIT: Tirzepatide reduces cardiovascular events in HFpEF plus obesity
CAD, PAD, and Valvular Heart Disease
CLEAR Outcomes: Bempedoic acid reduces MACE and MALE in patients with PAD
GLORIOUS: Restrictive versus liberal oxygenation during CPB-assisted surgery
GLORIOUS: GLP-1 agonist did not meet primary endpoint in CABG
CLEAR SYNERGY: Can routine spironolactone improve post-MI outcomes?
ENBALV: Edoxaban or warfarin as anticoagulant after bioprosthetic valve replacement?
Prospects in Prevention
ZODIAC: Can we improve lipid-lowering strategies in ACS?
KRAKEN: Encouraging phase 2 results of Lp(a)-lowering muvalaplin
Reconditioned pacemakers may save lives in low/middle-income countries
Novel small-interfering RNA effectively reduced Lp(a) in phase 2
Impactful Hypertension Strategies
Comparing dual antihypertensive combination therapies in a South Asian population
BPROAD: Intensive or standard BP treatment strategy in type 2 diabetes?
Innovative Studies in Heart Disease
Promising results for CRISPR-based therapy in ATTR-CM
NUDGE-FLU: Effect of science-informed letters on influenza vaccination rates
Related Articles

February 3, 2025
Promising results for CRISPR-based therapy in ATTR-CM
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com